Format

Send to

Choose Destination
Adv Exp Med Biol. 2018;1098:199-211. doi: 10.1007/978-3-319-97421-7_11.

Clinical Trial Design for Investigational Cardio-Regenerative Therapy.

Author information

1
School of Medicine & Public Health, University of Wisconsin-Madison, Madison, WI, USA. anr@medicine.wisc.edu.

Abstract

Human trials of cardio-regenerative biologic therapies are being performed worldwide to address a growing, unmet need for durable treatments of cardiovascular disease. A well-constructed clinical trial design for these novel therapies requires careful attention to defining a clear hypothesis, a patient population, and anticipated outcomes. The scope of screening, method of randomization, blinding approach, data monitoring, and statistical analysis plan are the foundational elements that must be addressed in any clinical trial. Although the experience of human trials involving extracellular matrix constructs for cardiovascular disease treatment is limited, numerous lessons have been learned in the field of cell therapy that are translatable across all biologic treatment options. Future progress in this field may include testing combinations of cells, gene-transfer agents, and matrix and identifying treatment responders versus nonresponders.

KEYWORDS:

Cardiomyopathy; Clinical trial; Heart failure; Myocardial infarction; Regenerative medicine; Stem cell; Treatment

PMID:
30238373
DOI:
10.1007/978-3-319-97421-7_11
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center